Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track

PRECISION BIOSCIENCES INC

2025-Q3 EPS reported -$6.14 revenue$60,000

Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.
Revenue <$0.1M, down from $0.6M YoY; R&D $13.4M, G&A $7.3M.
Cash $71.2M; expected runway into H2 2027 via cost cuts and potential near-term CAR T payments.
PBGENE-HBV Phase 1 dosing Cohort 3; late-breaking oral at AASLD on Nov 10.
PBGENE-DMD IND filing expected end-2025; Phase 1 start H1 2026, initial data H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.